炎性相关标志物对结直肠癌的预测价值

doi:10.3760/cma.j.cn371439-20220520-00109

摘要/Abstract

摘要：

肿瘤相关全身炎症反应是肿瘤进展的主要原因之一。血清中的炎性标志物,如中性粒细胞与淋巴细胞比值、淋巴细胞与单核细胞比值、全身炎症评分、格拉斯哥预后评分、预后营养指数、C-反应蛋白-白蛋白比值、淋巴细胞与C-反应蛋白比值、血小板与淋巴细胞比值均与结直肠癌（CRC）预后密切相关。进一步研究炎性相关标志物在CRC预后中的价值,将为CRC预后判断提供帮助。

关键词: 结直肠肿瘤, 预后, 生物标记

Abstract:

The cancer-associated systemic inflammatory response is one of the critical indicators of tumor progression. Serum systemic inflammatory markers, such as neutrophil-lymphocyte ratio, lymphocyte-monocyte ratio, systemic inflammation score, Glasgow prognostic score, prognostic nutritional index, C-reactive protein-albumin ratio, lymphocyte-C-reactive protein ratio, platelet-lymphocyte ratio, are associated with the prognosis of colorectal cancer （CRC）. Further research of the prognostic value of inflammatory marks in CRC can provide help for the prognosis of CRC.

Key words: Colorectal neoplasms, Prognosis, Biomarkers

何哲锋, 吴燚阳, 李振军, 应晓江. 炎性相关标志物对结直肠癌的预测价值[J]. 国际肿瘤学杂志, 2022, 49(9): 560-563.

He Zhefeng, Wu Yiyang, Li Zhenjun, Ying Xiaojiang. Predictive value of inflammatory markers in colorectal cancer[J]. Journal of International Oncology, 2022, 49(9): 560-563.

参考文献 37

[1]	Siegel RL, Miller KD, Fuchs HE, et al. Cancer statistics, 2022[J]. CA Cancer J Clin, 2022, 72(1): 7-33. DOI: 10.3322/caac.21708. doi: 10.3322/caac.21708
[2]	Tuomisto AE, Mäkinen MJ, Väyrynen JP. Systemic inflammation in colorectal cancer: underlying factors, effects, and prognostic significance[J]. World J Gastroenterol, 2019, 25(31): 4383-4404. DOI: 10.3748/wjg.v25.i31.4383. doi: 10.3748/wjg.v25.i31.4383
[3]	Katayama Y, Yamada T, Chihara Y, et al. Significance of inflammatory indexes in atezolizumab monotherapy outcomes in previously treated non-small-cell lung cancer patients[J]. Sci Rep, 2020, 10(1): 17495. DOI: 10.1038/s41598-020-74573-0. doi: 10.1038/s41598-020-74573-0 pmid: 33060826
[4]	Yang J, Guo X, Wang M, et al. Pre-treatment inflammatory indexes as predictors of survival and cetuximab efficacy in metastatic colorectal cancer patients with wild-type RAS[J]. Sci Rep, 2017, 7(1): 17166. DOI: 10.1038/s41598-017-17130-6. doi: 10.1038/s41598-017-17130-6 pmid: 29215037
[5]	Noh OK, Oh SY, Kim YB, et al. Prognostic significance of lymphocyte counts in colon cancer patients treated with FOLFOX chemotherapy[J]. World J Surg, 2017, 41(11): 2898-2905. DOI: 10.1007/s00268-017-4104-6. doi: 10.1007/s00268-017-4104-6 pmid: 28707088
[6]	Inamoto S, Kawada K, Okamura R, et al. Prognostic impact of the combination of neutrophil-to-lymphocyte ratio and Glasgow prognostic score in colorectal cancer: a retrospective cohort study[J]. Int J Colorectal Dis, 2019, 34(7): 1303-1315. DOI: 10.1007/s00384-019-03316-z. doi: 10.1007/s00384-019-03316-z pmid: 31177316
[7]	Feliciano EMC, Kroenke CH, Meyerhardt JA, et al. Association of systemic inflammation and sarcopenia with survival in nonmetastatic colorectal cancer: results from the C SCANS study[J]. JAMA Oncol, 2017, 3(12): e172319. DOI: 10.1001/jamaoncol.2017.2319. doi: 10.1001/jamaoncol.2017.2319
[8]	Verter E, Berger Y, Perl G, et al. Neutrophil-to-lymphocyte ratio predicts recurrence pattern in patients with resectable colorectal liver metastases[J]. Ann Surg Oncol, 2021, 28(8): 4320-4329. DOI: 10.1245/s10434-021-10000-6. doi: 10.1245/s10434-021-10000-6
[9]	Ugel S, Canè S, De Sanctis F, et al. Monocytes in the tumor microenvironment[J]. Annu Rev Pathol, 2021, 16: 93-122. DOI: 10.1146/annurev-pathmechdis-012418-013058. doi: 10.1146/annurev-pathmechdis-012418-013058 pmid: 33497262
[10]	Zhang LN, Xiao W, OuYang PY, et al. The prognostic impact of preoperative blood monocyte count in pathological T₃N₀M₀ rectal cancer without neoadjuvant chemoradiotherapy[J]. Tumour Biol, 2015, 36(10): 8213-8219. DOI: 10.1007/s13277-015-3560-6. doi: 10.1007/s13277-015-3560-6
[11]	Sasaki A, Kai S, Endo Y, et al. Prognostic value of preoperative peripheral blood monocyte count in patients with colorectal liver metastasis after liver resection[J]. J Gastrointest Surg, 2007, 11(5): 596-602. DOI: 10.1007/s11605-007-0140-0. doi: 10.1007/s11605-007-0140-0 pmid: 17468918
[12]	Yasui K, Shida D, Nakamura Y, et al. Postoperative, but not preoperative, inflammation-based prognostic markers are prognostic factors in stage Ⅲ colorectal cancer patients[J]. Br J Cancer, 2021, 124(5): 933-941. DOI: 10.1038/s41416-020-01189-6. doi: 10.1038/s41416-020-01189-6
[13]	Thiagarajan S, Tan JW, Zhou S, et al. Postoperative inflammatory marker surveillance in colorectal peritoneal carcinomatosis[J]. Ann Surg Oncol, 2021, 28(11): 6625-6635. DOI: 10.1245/s10434-020-09544-w. doi: 10.1245/s10434-020-09544-w pmid: 33655363
[14]	Chan JC, Chan DL, Diakos CI, et al. The lymphocyte-to-monocyte ratio is a superior predictor of overall survival in comparison to established biomarkers of resectable colorectal cancer[J]. Ann Surg, 2017, 265(3): 539-546. DOI: 10.1097/SLA.0000000000001743. doi: 10.1097/SLA.0000000000001743 pmid: 27070934
[15]	Shibutani M, Maeda K, Nagahara H, et al. The prognostic value of the systemic inflammatory score in patients with unresectable metastatic colorectal cancer[J]. Oncol Lett, 2018, 16(1): 666-672. DOI: 10.3892/ol.2018.8628. doi: 10.3892/ol.2018.8628 pmid: 29928454
[16]	Suzuki Y, Okabayashi K, Hasegawa H, et al. Comparison of preoperative inflammation-based prognostic scores in patients with colorectal cancer[J]. Ann Surg, 2018, 267(3): 527-531. DOI: 10.1097/SLA.0000000000002115. doi: 10.1097/SLA.0000000000002115 pmid: 27984214
[17]	Yamamoto T, Kawada K, Obama K. Inflammation-related biomarkers for the prediction of prognosis in colorectal cancer patients[J]. Int J Mol Sci, 2021, 22(15): 8002. DOI: 10.3390/ijms22158002. doi: 10.3390/ijms22158002
[18]	Frühling P, Hellberg K, Ejder P, et al. The prognostic value of C-reactive protein and albumin in patients undergoing resection of colorectal liver metastases. A retrospective cohort study[J]. HPB (Oxford), 2021, 23(6): 970-978. DOI: 10.1016/j.hpb.2020.10.019. doi: 10.1016/j.hpb.2020.10.019
[19]	Tokunaga R, Sakamoto Y, Nakagawa S, et al. Comparison of systemic inflammatory and nutritional scores in colorectal cancer patients who underwent potentially curative resection[J]. Int J Clin Oncol, 2017, 22(4): 740-748. DOI: 10.1007/s10147-017-1102-5. doi: 10.1007/s10147-017-1102-5 pmid: 28213742
[20]	Tominaga T, Nonaka T, Hisanaga M, et al. Prognostic value of the preoperative prognostic nutritional index in oldest-old patients with colorectal cancer[J]. Surg Today, 2020, 50(5): 449-459. DOI: 10.1007/s00595-019-01910-w. doi: 10.1007/s00595-019-01910-w pmid: 31720800
[21]	Zhou J, Wei W, Hou H, et al. Prognostic value of C-reactive protein, glasgow prognostic score, and C-reactive protein-to-albumin ratio in colorectal cancer[J]. Front Cell Dev Biol, 2021, 9: 637650. DOI: 10.3389/fcell.2021.637650. doi: 10.3389/fcell.2021.637650
[22]	Matsuoka H, Ando K, Hu Q, et al. Postoperative C-reactive protein/albumin ratio is a biomarker of risk of recurrence and need for adjuvant chemotherapy for stage Ⅲ colorectal cancer[J]. Int J Clin Oncol, 2020, 25(7): 1318-1326. DOI: 10.1007/s10147-020-01672-3. doi: 10.1007/s10147-020-01672-3 pmid: 32279124
[23]	Ide S, Toiyama Y, Okugawa Y, et al. Clinical significance of C-reactive protein-to-albumin ratio with rectal cancer patient undergoing chemoradiotherapy followed by surgery[J]. Anticancer Res, 2017, 37(10): 5797-5804. DOI: 10.21873/anticanres.12022. doi: 10.21873/anticanres.12022 pmid: 28982904
[24]	Dolan RD, McSorley ST, Park JH, et al. The prognostic value of systemic inflammation in patients undergoing surgery for colon cancer: comparison of composite ratios and cumulative scores[J]. Br J Cancer, 2018, 119(1): 40-51. DOI: 10.1038/s41416-018-0095-9. doi: 10.1038/s41416-018-0095-9
[25]	Suzuki S, Akiyoshi T, Oba K, et al. Comprehensive comparative analysis of prognostic value of systemic inflammatory biomarkers for patients with stage Ⅱ/Ⅲ colon cancer[J]. Ann Surg Oncol, 2020, 27(3): 844-852. DOI: 10.1245/s10434-019-07904-9. doi: 10.1245/s10434-019-07904-9
[26]	Okugawa Y, Toiyama Y, Yamamoto A, et al. Lymphocyte- C-reactive protein ratio as promising new marker for predicting surgical and oncological outcomes in colorectal cancer[J]. Ann Surg, 2020, 272(2): 342-351. DOI: 10.1097/SLA.0000000000003239. doi: 10.1097/SLA.0000000000003239
[27]	Páramo JA. Microvascular thrombosis and clinical implications[J]. Med Clin (Barc), 2021, 156(12): 609-614. DOI: 10.1016/j.medcli.2020.12.042. doi: 10.1016/j.medcli.2020.12.042
[28]	Josa V, Ferenczi S, Szalai R, et al. Thrombocytosis and effects of IL-6 knock-out in a Colitis-Associated cancer model[J]. Int J Mol Sci, 2020, 21(17): 6218. DOI: 10.3390/ijms21176218. doi: 10.3390/ijms21176218
[29]	Braun A, Anders HJ, Gudermann T, et al. Platelet-cancer interplay: molecular mechanisms and new therapeutic avenues[J]. Front Oncol, 2021, 11: 665534. DOI: 10.3389/fonc.2021.665534. doi: 10.3389/fonc.2021.665534
[30]	Yu L, Guo Y, Chang Z, et al. Bidirectional interaction between cancer cells and platelets provides potential strategies for cancer therapies[J]. Front Oncol, 2021, 11: 764119. DOI: 10.3389/fonc.2021.764119. doi: 10.3389/fonc.2021.764119
[31]	Ishizuka M, Nagata H, Takagi K, et al. Preoperative thrombocytosis is associated with survival after surgery for colorectal cancer[J]. J Surg Oncol, 2012, 106(7): 887-891. DOI: 10.1002/jso.23163. doi: 10.1002/jso.23163 pmid: 22623286
[32]	Pedrazzani C, Mantovani G, Fernandes E, et al. Assessment of neutrophil-to-lymphocyte ratio, platelet-to-lymphocyte ratio and platelet count as predictors of long-term outcome after R0 resection for colorectal cancer[J]. Sci Rep, 2017, 7(1): 1494. DOI: 10.1038/s41598-017-01652-0. doi: 10.1038/s41598-017-01652-0 pmid: 28473700
[33]	Bilen MA, Martini DJ, Liu Y, et al. The prognostic and predictive impact of inflammatory biomarkers in patients who have advanced-stage cancer treated with immunotherapy[J]. Cancer, 2019, 125(1): 127-134. DOI: 10.1002/cncr.31778. doi: 10.1002/cncr.31778 pmid: 30329148
[34]	Sato R, Oikawa M, Kakita T, et al. A decreased preoperative platelet-to-lymphocyte ratio, systemic immune-inflammation index, and pan-immune-inflammation value are associated with the poorer survival of patients with a stent inserted as a bridge to curative surgery for obstructive colorectal cancer[J]. Surg Today, 2022. In press. DOI: 10.1007/s00595-022-02575-8. doi: 10.1007/s00595-022-02575-8
[35]	Cho U, Sung YE, Kim MS, et al. Prognostic role of systemic inflammatory markers in patients undergoing surgical resection for oral squamous cell carcinoma[J]. Biomedicines, 2022, 10(6): 1268. DOI: 10.3390/biomedicines10061268. doi: 10.3390/biomedicines10061268
[36]	Kim JH, Lee JY, Kim HK, et al. Prognostic significance of the neutrophil-to-lymphocyte ratio and platelet-to-lymphocyte ratio in patients with stage Ⅲ and Ⅳ colorectal cancer[J]. World J Gastroenterol, 2017, 23(3): 505-515. DOI: 10.3748/wjg.v23.i3.505. doi: 10.3748/wjg.v23.i3.505
[37]	Erstad DJ, Taylor MS, Qadan M, et al. Platelet and neutrophil to lymphocyte ratios predict survival in patients with resectable colorectal liver metastases[J]. Am J Surg, 2020, 220(6): 1579-1585. DOI: 10.1016/j.amjsurg.2020.05.003. doi: 10.1016/j.amjsurg.2020.05.003 pmid: 32580870